Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
09/03/2008
Trade Name:
Valtrex
Generic Name or Proper Name (*):
valacyclovir
Indications Studied:
Chickenpox; active or at risk for herpes virus infection
Label Changes Summary:
New indication for treatment of chickenpox in pediatric patients 2 to <18 years based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by safety and extrapolated efficacy data from 3 randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric patients with chickenpox The efficacy and safety of valacyclovir have not been established in pediatric patients: o <12 years of age with cold sores o<18 years of age with genital herpes o<18 years of age with herpes zoster o<2 years of age with chickenpox, ofor suppressive therapy following neonatal HSV infection Adverse events similar to that of adults Information on PK parameters, AEs, clinical studies, and preparation of an extemporaneous formulation
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B, P
Sponsor:
GlaxoSmithKline
Pediatric Exclusivity Granted Date:
02/26/2008
NNPS:
FALSE'
Therapeutic Category:
Antiviral
-
-